Muneyoshi Kuroyama
Overview
Explore the profile of Muneyoshi Kuroyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sakura K, Kuroyama M, Shintani Y, Funaki S, Atagi S, Kadota Y, et al.
Cancer Immunol Immunother
. 2024 Oct;
73(12):243.
PMID: 39358654
The hemagglutinating virus of Japan envelope (HVJ-E) is an inactivated Sendai virus particle with antitumor effect and inducing antitumor immunity. However, its dosage and efficacy have not been verified. We...
2.
Koba T, Takeda Y, Narumi R, Shiromizu T, Nojima Y, Ito M, et al.
ERJ Open Res
. 2021 Mar;
7(1).
PMID: 33778046
There is an unmet need for novel biomarkers in the diagnosis of multifactorial COPD. We applied next-generation proteomics to serum extracellular vesicles (EVs) to discover novel COPD biomarkers. EVs from...
3.
Tanaka S, Asakawa R, Komuta K, Tanizaki S, Kanai T, Kuroyama M, et al.
Respir Med Case Rep
. 2020 Nov;
31:101266.
PMID: 33134073
Immune checkpoint inhibitors (ICIs) improved the prognosis of patients with advanced lung cancers. The combination therapy of cytotoxic drugs and ICI is approved as first-line chemotherapy in non-small-cell lung cancer...
4.
Futami S, Takimoto T, Nakagami F, Satoh S, Hamaguchi M, Kuroyama M, et al.
BMC Infect Dis
. 2019 Jul;
19(1):598.
PMID: 31288744
Background: In Japan and other countries, the number of patients with syphilis is increasing year by year. Recently, the cases of the pulmonary involvement in patients with secondary syphilis have...
5.
Otsuka T, Tanaka A, Azukizawa H, Sasaki S, Ishijima M, Matsuki T, et al.
Int Cancer Conf J
. 2019 Jun;
6(1):38-41.
PMID: 31149467
We report a case of a 65-year-old woman with stage IV lung adenocarcinoma who experienced Stevens-Johnson syndrome (SJS) during afatinib therapy. The patient received afatinib as the first-line therapy after...
6.
Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, et al.
JCI Insight
. 2018 Oct;
3(19).
PMID: 30282824
Background: The PD-1-blocking antibody nivolumab persists in patients several weeks after the last infusion. However, no study has systematically evaluated the maximum duration that the antibody persists on T cells...
7.
Koba T, Hirata H, Kijima T, Naito Y, Hamaguchi M, Suga Y, et al.
Gan To Kagaku Ryoho
. 2018 Sep;
45(9):1335-1337.
PMID: 30237376
Background: The efficacy and safety of chemotherapy for patients with lung cancer who are in need of intensive care, such as invasive mechanical ventilation, have not been established. Case: A...
8.
Jin Y, Takeda Y, Kondo Y, Tripathi L, Kang S, Takeshita H, et al.
Sci Rep
. 2018 Mar;
8(1):5145.
PMID: 29572511
Chronic obstructive pulmonary disease (COPD) has been recently characterized as a disease of accelerated lung aging, but the mechanism remains unclear. Tetraspanins have emerged as key players in malignancy and...
9.
Otsuka T, Nojiri T, Minami S, Hosoda H, Kuroyama M, Hirata H, et al.
Anticancer Res
. 2017 Jul;
37(7):3505-3512.
PMID: 28668839
Aim: To identify predictive markers for efficacy of combination bevacizumab and carboplatin-paclitaxel treatment in patients with advanced non-squamous non-small cell lung cancer (NSCLC). Patients And Methods: Twenty patients received carboplatin...
10.
Koba T, Kijima T, Takimoto T, Hirata H, Naito Y, Hamaguchi M, et al.
Medicine (Baltimore)
. 2017 Feb;
96(6):e6087.
PMID: 28178168
Rationale: Most of nonsmall cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) activating mutations eventually acquire resistance to the first EGFR-tyrosine kinase inhibitors (TKIs) therapy after varying...